Literature DB >> 8564918

Negative symptoms and affective disturbance in schizophrenia and related disorders.

A K Malla1.   

Abstract

OBJECTIVE: To review the data and discuss clinical recommendations for treating negative symptoms of schizophrenia. Negative symptoms (e.g., poverty of thought, affective blunting) have been regarded as part of schizophrenia since Kraepelin's early descriptions, although they remain a subject of controversy. For example, it is unclear if negative symptoms are distinct from other psychiatric symptoms such as depression, or are in actuality depression within schizophrenia. Recent evidence suggests that negative symptoms are independent of depression.
METHOD: Factor analytic studies have suggested that a negative factor (loss of affect, volition, poverty of thinking) may be distinguished from other components and is separable from a depression factor. Experimental use of vignettes have also been useful in the assessment of negative symptoms. A second controversial area is whether or not the presence or absence of affect is the fundamental issue separating schizophrenia from other psychoses.
RESULTS: A continuum of psychosis has been hypothesized, with unipolar psychotic depression at one pole and schizophrenia with defect state at the other. Within this proposed continuum, negative symptoms are associated only with schizophrenia without affect and with defect state schizophrenia. As such, variation in affect could be a primary determinant of the type of psychosis.
CONCLUSION: It appears that negative symptoms are a distinct aspect of schizophrenia and may aid in our understanding of psychotic disorders.

Entities:  

Mesh:

Year:  1995        PMID: 8564918     DOI: 10.1177/070674379504007s05

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  1 in total

1.  Further characterization of the predictive validity of the Brattleboro rat model for antipsychotic efficacy.

Authors:  D Feifel; P D Shilling; G Melendez
Journal:  J Psychopharmacol       Date:  2010-11-24       Impact factor: 4.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.